Ucb Biopharma Srl 2025 IR
The report highlights UCB's strong financial and operational performance in 2025, delivering a 26% revenue growth to ’7,741 million, driven by its five key growth drivers: BIMZELX®, RYSTIGGO®, ZILBRYSQ®, FINTEPLA®, and EVENITY®. The company advanced its pipeline with the U.S. FDA approval of KYGEVVI™ for thymidine kinase 2 deficiency (TK2d) and initiated several pediatric Phase 3 studies. On sustainability, UCB made progress toward its net-zero targets, achieving a 35.8% absolute reduction in Scope 1, 2, and 3 (excluding category 1) emissions compared to its 2019 baseline, and was awarded an A rating for climate change by CDP. Additionally, UCB announced plans for a state-of-the-art biologics manufacturing facility in the U.S. to support future patient demand.
Company: Ucb Biopharma Srl
Year: 2025
Type: IR
Pages: 292
Ucb Biopharma Srl
Integrated Annual Report
The report highlights UCB's strong financial and operational performance in 2025, delivering a 26% revenue growth to ’7,741 million, driven by its five key growth drivers: BIMZELX®, RYSTIGGO®, ZILBRYSQ®, FINTEPLA®, and EVENITY®. The company advanced its pipeline with the U.S. FDA approval of KYGEVVI™ for thymidine kinase 2 deficiency (TK2d) and initiated several pediatric Phase 3 studies. On sustainability, UCB made progress toward its net-zero targets, achieving a 35.8% absolute reduction in Scope 1, 2, and 3 (excluding category 1) emissions compared to its 2019 baseline, and was awarded an A rating for climate change by CDP. Additionally, UCB announced plans for a state-of-the-art biologics manufacturing facility in the U.S. to support future patient demand.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees